Role of selenium in viral infections with a major focus on SARS-CoV-2
Many patients on GLP-1s unintentionally undereat protein, and over time, this can contribute to fatigue, muscle loss, slower metabolism, weakness, and even weight loss plateaus
We've known for decades that it's a combination of biology, genetics, physiology, environment, social drivers of health
The closest pipeline candidates are orforglipron, the first non-peptide oral GLP-1 from Eli Lilly, with an FDA decision anticipated in 2026, and retatrutide, a triple GLP-1/GIP/glucagon agonist in phase 3
Liver protein expression in NASH mice on a high-fat diet: response to multi-mineral intervention